Blog
We select a preclinical drug evaluation provider based on scientific fit, execution control, and the usefulness of the delivered evidence. Our review of the a
September 30, 2026
No Comments
We select a preclinical drug evaluation provider based on scientific fit, execution control, and the usefulness of the delivered evidence. Our review of the a
We avoid allowing a familiar assay to substitute for the underlying biological question when we build drug-efficacy platforms. The drug-efficacy platform method plan reflects both scientific
We conduct cell therapy evaluation through an integrated workflow covering product identity, potency, biodistribution, persistence, and safety. The biological question and development stage guide the study
